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Abstract 29 
 30 
The use of opioids has grown substantially over the past two decades reaching the dimensions of a 31 
global epidemic. These drugs have effects on multiple levels of the endocrine system through 32 
mechanisms which are still not fully elucidated, and awareness of their endocrine sequelae is vital for 33 
all specialists prescribing or managing patients on them. Hypogonadism is the most well recognised 34 
consequence of opioid use (prevalence 21-86%) which, however, may remain undiagnosed with 35 
potential adverse outcomes for the patients. Although less frequent, cortisol deficiency can be also 36 
found. Furthermore, there is negative impact on bone health (with reduced bone mineral density and 37 
increased fracture risk) and occasionally hyperprolactinaemia, whereas the clinical significance of 38 
alterations in other hormones remains to be clarified.  Discontinuation or reduction of the opioid and, 39 
in cases of chronic pain, consideration of alternative therapies for pain relief are potential 40 
management options. Hormonal replacement, especially when the above measures are not practically 41 
feasible, needs to be considered. Further studies are needed to clearly establish the prevalence of 42 
hormonal abnormalities with various regimes, doses and routes of opioids and to address reliably the 43 
long-term benefits and risks of hormonal treatment in patients on opioids. Until evidence-based, safe 44 
and cost-effective clinical guidelines become available, periodical assessment of the gonadal and 45 
adrenal function (particularly when relevant clinical manifestations are present) and evaluation of the 46 
bone health status are advised.   47 
   48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
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Introduction  57 
 58 
Opium is acquired in the dried latex form from the seed pod of the opium poppy (Papaver 59 
somniferum), initially cultivated by the Sumerians at around 4000 BC. The naturally occurring 60 
alkaloids of opium and the drugs synthesized from it are described as ‘opiates’, whilst all natural or 61 
synthetic chemicals that bind to opioid receptors are included in the term ‘opioids’. The main classes 62 
of opioids include natural opiates (alkaloids in the resin of the opium poppy, mainly morphine, 63 
codeine and thebaine), esters of morphine [e.g. morphine diacetate or diamorphine (heroin)], semi-64 
synthetic opioids (produced from the natural opiates or morphine esters, e.g. hydromorphone, 65 
hydrocodone, oxycodone, oxymorphone, buprenorphine), fully synthetic opioids (e.g. fentanyl, 66 
pethidine, methadone, tramadol) and endogenous opioid peptides produced in the body (e.g. 67 
endorphins, enkephalins)
1
. 68 
Opioids exert their actions by binding to receptors which belong to the family of G-protein 69 
coupled ones, and their activation produces a range of different effects
1
. There are many types of 70 
opioid receptors with the three main being μ, κ, δ (that are naloxone sensitive), whereas the nociceptin 71 
receptor, with effects not reversed by naloxone, was discovered in 1994
2
. The opioids used in clinical 72 
practice have various indications and are mainly offered as analgesic agents (Table 1), whereas heroin 73 
is used as a recreational drug due to its euphoric effects (illicit use).  The most commonly available 74 
opioids (morphine, codeine, fentanyl, and their derivatives, methadone, tramadol, pethidine) are 75 
primarily μ-receptors agonists, whilst buprenorphine and pentazocine are mixed agonists/antagonists3. 76 
Pentazocine acts as a partial agonist on δ- and κ-receptors and as an antagonist on the μ-receptor, 77 
whilst buprenorphine has partial agonist activity on μ- and nociceptin receptors and antagonist activity 78 
on κ-receptors4. 79 
The use of opioids has grown over the past two decades; between 2000 and 2014, it increased 80 
216% in USA and 210% globally making opioid consumption a real global epidemic
5
. Notably, in 81 
2014, USA used around 69% of the world’s supply of opioids; prescribers involve a wide range of 82 
health professionals including pain physicians, family physicians, orthopaedic surgeons, 83 
anaesthesiologists, psychiatrists, physical medicine and rehabilitation specialists
5
. Data from the UK 84 
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Clinical Practice Research Datalink confirm a significant rise in strong opioid prescriptions 85 
(buprenorphine, fentanyl, morphine and oxycodone) between 2000 and 2010, with the majority 86 
administered for non-cancer patients
6
; in this report, the number of strong opioid users increased from 87 
9479 to 53,666 during the study period. In addition, prescription of long-acting opioids in patients 88 
with chronic non-cancer pain has been associated with a significantly elevated risk of all-cause and of 89 
cardiovascular-specific mortality, compared with analgesic anticonvulsants or low dose tricyclic 90 
antidepressants
5, 7
. 91 
Exogenous opioids can have various effects on the endocrine system, which, nonetheless, may 92 
remain underdiagnosed with potential adverse sequelae for the patients. The aim of this manuscript is 93 
to provide a review of these effects and their underlying mechanisms, to discuss their clinical 94 
significance and management and to identify areas requiring further research in this field. 95 
 96 
Hypothalamo-Pituitary-Gonadal axis 97 
 98 
Opioids, both endogenous and exogenous, modulate gonadal function primarily by acting on 99 
opioid ε-receptors in the hypothalamus8. This leads to reduced release or disruption of the normal 100 
pulsatility of gonadotropin-releasing hormone (GnRH) secretion and reduction of the release of 101 
luteinising hormone (LH) and follicle-stimulating hormone (FSH - to a lesser extent) from the 102 
pituitary gland, and of testosterone or oestradiol from the gonads
9-16
. Opioids may also directly inhibit 103 
the pituitary release of gonadotropins
17
. Hyperprolactinaemia that can be occasionally caused by 104 
opioids may contribute to their suppressive effects on the HPG axis
9
. Opioids have also direct effects 105 
on the gonads: these include decreased production of sperm, testicular interstitial fluid, and intra-106 
testicular testosterone
18
.  107 
The effects of long-term opioid use on the gonadal status have been studied extensively in the past 108 
four decades and the reported prevalence of opioid-induced hypogonadism ranges between 21% and 109 
86%
10-16, 19
. This wide range is attributed to the heterogeneity of the studies (differences in the 110 
populations assessed, variations in the type, dose, route and duration of opioid administration, 111 
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potential impact of pain, of other comorbidities and of concurrent medications, and possibly 112 
differences in the age of the patients included). 113 
The initial studies involved mainly heroin addicts and patients on methadone for maintenance and 114 
had demonstrated reduction of testosterone levels in males, with an associated reduction in LH and/or 115 
FSH
20-22
. The decrease in testosterone occurs within a few hours of opioid administration; in a study 116 
of 13 males on acetylmethadol for opioid dependence, there was significant reduction of testosterone 117 
four hours after the ingestion of the drug, with the levels remaining low around 24 hours after the drug 118 
administration and returning to baseline values 48 hours post-acetylmethadol use
23
. Woody et al. had 119 
similar results, albeit the duration of recovery was shorter
11
. In another study with male heroin 120 
addicts, recovery of testosterone to normal occurred after about one month of drug abstinence
21
. 121 
Furthermore, methadone has a dose-dependent effect on the testosterone levels of heroin addicts on 122 
methadone detoxification
22
. In female heroin addicts, amenorrhoea and galactorrhoea may be 123 
present
24
; nonetheless, series systematically assessing this group of patients are not available. 124 
Hypogonadism is also present in both male and female patients on opioids (oral, transdermal or 125 
intrathecal) for cancerous or non-cancerous pain in cohort or cross-sectional studies; it should be 126 
noted, however, that other factors may also contribute to the hypogonadism including pain 127 
pathophysiology, pain comorbidities and patients’ age and these need to be taken into account when 128 
interpreting their results
12-14, 16, 25-29
. The effects on the HPG axis begin as soon as the opioid is taken
12, 129 
13, 16, 30
 and the hormonal changes are dose-related
13, 31
. The resultant clinical manifestations include 130 
erectile dysfunction, decreased libido, infertility, fatigue, depression, hot flushes and night sweats in 131 
males
13, 16, 27-29
 and reduced libido, ameno- or oligomenorrhoea with anovulation in premenopausal 132 
females
16
. In postmenopausal women, LH and FSH levels can be decreased
16
. The prevalence of 133 
hypogonadism is higher in men than in women
 
taking oral opioids for chronic non-cancer pain
15
. In 134 
premenopausal chronic pain patients, the suppression of LH may be less profound when opioids are 135 
administered orally/transdermally compared with the intrathecal route
9
. Notably, chronic use of long-136 
acting opioids is associated with greater odds of androgen deficiency compared to chronic use of 137 
short-acting ones
31, 32
. Furthermore, transdermal fentanyl, methadone, and oxycodone (long- and 138 
short-acting formulations combined) are associated with higher odds of androgen deficiency when 139 
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compared to hydrocodone
33
. It should be pointed out, however, that these findings reflect the 140 
observations at the doses used for different opioids in the various studies. Buprenorphine, a partial µ-141 
receptor agonist and κ-receptor antagonist used as maintenance for opioid dependence or for the 142 
management of acute/persistent pain results in less severe hypogonadism when compared to 143 
methadone
34, 35
. Reduction in the dose or cessation of therapy reverses the hypogonadism 
26, 30, 36, 37
 but 144 
the time course of this has not been systematically studied.  145 
Despite the abundance of evidence indicating that opioids lead to hypogonadotropic 146 
hypogonadism, this condition remains underdiagnosed in daily practice; this may relate with lack of 147 
symptoms reporting by the patients combined with the underappreciation of this common problem 148 
amongst the clinicians. Currently, there is no consensus or clinical guidelines for the diagnosis and 149 
management of opioid-induced hypogonadism. Manifestations of hypogonadism should be enquired 150 
before, as well as during opioid treatment and patients should be educated on this potential side effect 151 
and encouraged to report hypogonadal symptoms should they experience any. Laboratory evaluations 152 
need to be taken periodically (and also when changing dose or regime of opioid) and include 153 
measurement of blood testosterone (in a morning sample before 10 am) and gonadotropins in men and 154 
oestradiol and gonadotropins in women (combined with menstrual history)
38
.  Measurement of 155 
prolactin (PRL) and taking into account the impact of other medications and co-morbidities, as well as 156 
exclusion of other causes of hypogonadotropic hypogonadism are also advised.  157 
Management of the opioid-induced hypogonadism includes discontinuation or reduction of the 158 
dose of the opioid and consideration of alternative therapies for patients on chronic pain requiring 159 
pain relief. When the above measures are not viable, gonadal hormone replacement should be 160 
considered with a number of studies showing beneficial effects. Aloisi et al., in a series of nine males 161 
(aged between 44 and 75 years) on epidural morphine for non-oncological chronic pain treated with 162 
testosterone gel for 12 months, demonstrated improvement in the sexual dimension of the Aging 163 
Males’ Symptoms scale and in the Mental Index of the SF-36 questionnaire39. The patients also 164 
reported increase in the growth of body hair and improved appetite and their prostate-specific antigen 165 
(PSA) levels remained within normal limits. None of the Profile of Mood State subscale scores or 166 
Centre for Epidemiological Studies Depression Scale ratings showed significant changes
39
. Daniell et 167 
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al., in an open-label pilot study on 16 men (aged between 34 and 55 years) with opioid-induced 168 
androgen deficiency (on oral sustained release oxycodone or oral methadone for pain syndromes) 169 
offered testosterone transdermal patches for 24 weeks, found improvement in androgen deficiency 170 
symptoms, sexual function, psychological well-being and depressed mood by using validated 171 
questionnaires, as well as of the haemoglobin and haematocrit
40
. Basaria et al., in a randomised, 172 
double-blind, parallel placebo-controlled trial of 65 males (aged between 18 and 64 years) with 173 
opioid-induced androgen deficiency and chronic non-cancer pain, randomised to receive transdermal 174 
testosterone or placebo for 14 weeks, found that men in the testosterone arm demonstrated greater 175 
improvement in mechanical and pressure hyperalgesia and in sexual desire, as well as reduction in fat 176 
mass
41; elevation in PSA >4 ng/ml was seen in two patients, one in each group, and erythrocytosis 177 
occurred in neither group. Notably, Huang et al., in a placebo-controlled, double-blind randomized 178 
trial from the same centre of 64 non-diabetic men (aged between 18 and 64 years) on opioid 179 
analgesics for chronic non-cancer pain and morning total testosterone <12 nmol/L (as measured by 180 
liquid chromatography-tandem mass spectrometry), randomised to 14 weeks of transdermal 181 
testosterone gel or placebo gel daily, found that changes in lipid profile, fasting glucose and insulin, 182 
homeostatic model assessment for insulin resistance and C-reactive protein were similar from baseline 183 
to the end of treatment in both groups; glucose and insulin response to 75 gr oral glucose load, 184 
inflammatory markers and adipokines also did not differ between the two groups
42
. However, the 185 
duration of this study was not long enough to evaluate cardiovascular safety of testosterone therapy in 186 
these patients. In contrast to their male counterparts, series looking at gonadal hormone replacement 187 
in opioid-induced hypogonadism in women are not available.  188 
In summary, opioid use has an inhibitory effect on the HPG axis through action at various levels 189 
leading to hypogonadism. Discontinuation or reduction in the dose of opioid can reverse this sequela 190 
but when this is not possible, gonadal hormone treatment needs to be considered. Adequately powered 191 
well-designed studies are needed to establish the long-term benefits and risks of hormone replacement 192 
in this group of patients, as well as the potential impact of hormonal treatment on pain sensitivity and 193 
on the recovery of patients on methadone for opioid use disorder. 194 
 195 
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Hypothalamo-pituitary-adrenal axis 196 
 197 
Opioids suppress the HPA axis mainly at the hypothalamic-pituitary level by inhibiting 198 
corticotropin-releasing hormone (CRH) and vasopressin secretion and by reducing their effect on 199 
adrenocorticotropic hormone (ACTH) and cortisol release
43-47
. The receptors involved are not entirely 200 
known but κ- are considered to be the predominant type; δ-receptors have also been implicated8, 48, 49. 201 
Nonetheless, the increasing evidence of secondary adrenal insufficiency in patients receiving μ-202 
receptor agonists suggests a potential role of this subtype in the opioid-induced regulation of HPA 203 
axis (morphine, hydromorphone, methadone, tramadol, diamorphine, fentanyl and loperamide act 204 
predominantly through this receptor)
36, 37, 50-54
. This is also supported by the observation that human 205 
subjects carrying the A118G single nucleotide polymorphism of the μ-receptor encoding gene 206 
OPRM1 (which has been shown to increase the receptor's binding affinity to β-endorphin) show 207 
blunted ACTH response to metyrapone and exaggerated cortisol release to naloxone
55, 56
. Opioids 208 
have also direct effects on the adrenal glands, independently of their effect on the hypothalamo-209 
pituitary unit; naloxone administration in patients with hypothalamo-pituitary disconnection led to 210 
higher cortisol (but not ACTH) levels compared with saline
57
 and β-endorphin suppressed ACTH-211 
stimulated cortisol production in isolated human adrenocortical cells
58
. 212 
Acute administration of opioids in animals results in an exaggerated response of the HPA axis 213 
which may be followed by a rebound decrease of its activity
59, 60
. Data from animal studies assessing 214 
the effects of chronic administration of opioids on ACTH and glucocorticoid release are conflicting 215 
showing activation
61
, suppression
59
 or no effect
62
.  216 
Single administration of various opioids (morphine, heroin, buprenorphine, remifentanil) in normal 217 
subjects results in suppression of ACTH and glucocorticoid secretion, blunted pituitary-adrenal 218 
response to CRH, and diminished cortisol response to psychosocial or surgical stress
45, 46, 63-65
. 219 
Notably, gender may play a role in the effect of opioids on the HPA axis. Women demonstrate a 220 
greater sensitivity to opioid receptor antagonists (naloxone and naltrexone) on their cortisol response 221 
compared to men suggesting sex differences in the endogenous opioid system
66-68
. Menstrual cycle 222 
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may also be implicated with a study showing that women in the luteal phase of their cycle had greater 223 
naltrexone-induced increases in serum cortisol than women in the early follicular phase
69
.  224 
In addition, diamorphine has an acute suppressive effect on HPA axis in heroin dependent addicts 225 
on heroin-assisted treatment
70
. Opioid dependent patients on maintenance treatment with intravenous 226 
diacetylmorphine have reduced serum levels of vasopressin and cortisol compared to healthy 227 
controls
43
. It is of note that in heroin addicts there is a disturbed cortisol circadian rhythm with lower 228 
morning cortisol levels compared with controls
65, 71
. 229 
Several case reports documenting secondary adrenal insufficiency after oral or transdermal opioid 230 
administration of variable duration (including even of a few days) mainly for pain relief have been 231 
published
36, 37, 50-54
. The accurate prevalence of adrenal insufficiency in these patients has not been 232 
clearly defined and chronic pain can be a major confounder (chronic pain has been associated with 233 
loss of the diurnal variation of blood cortisol, lower morning blood cortisol and 24-hour urinary free 234 
cortisol levels compared with controls and hyper-reactive ACTH release to CRH stimulation)
72, 73
. 235 
Aloisi et al. showed that intrathecal administration of morphine (0.9 mg/day) for 15 days in patients 236 
with persistent severe pain led to reduction in the blood cortisol levels with an immediate effect from 237 
Day 1 to Day 15 in both sexes; the levels rose on Day 16, 24 hours after the opioid withdrawal
30
. In 238 
contrast, transdermal buprenorphine (35mcg/h every 72 hours) for acute/persistent pain for six months 239 
did not inhibit the HPA axis. Gibb et al., in a series of 48 patients attending chronic tertiary pain 240 
clinics and treated with long-term opioid analgesia (tramadol, oxycodone, morphine sulphate, fentanyl 241 
or buprenorphine patch, dihydrocodeine – median daily opioid dose 68 mg as determined by 242 
morphine sulphate equivalent dose) for at least 6 months and no recent exposure to exogenous 243 
glucocorticoids, found 8.00 am blood cortisol <100 nmol/L in 8% of them and failure to respond to 244 
synthetic ACTH stimulation (peak cortisol <430 nmol/l) in 6%
74
. When focusing on the 33 patients on 245 
high-dose opioid analgesia (excluding tramadol and dihydrocodeine), approximately 10% of those 246 
assessed had an initial suboptimal cortisol response to synthetic ACTH. Intrathecal administration of 247 
morphine or hydromorphine in 72 patients with non-malignant pain (mean daily dose 4.8 ± 3.2 mg 248 
and mean duration of treatment 26.6 ± 16.3 months) resulted in basal cortisol levels <5 μg/dl and peak 249 
cortisol value <18 μg/dl during an insulin tolerance test (ITT) in 9% and 15% of them, respectively16; 250 
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one of the patients in this series developed Addisonian crisis during pneumonia. Furthermore, 33% of 251 
20 chronic pain patients receiving chronic pump intrathecal morphine infusion (0.2-10 mg/day) and 252 
50% of 20 patients on oral morphine (60-120 mg/day) demonstrated hypoadrenalism (defined as 253 
stimulated cortisol levels during ITT <18 μg/dl)75. Additionally, there is reduction of the adrenal 254 
androgen dehydroepiandrosterone sulfate levels during opioid therapy in patients with chronic non-255 
malignant pain
14, 75, 76
. Factors predicting the development of abnormal cortisol stress response are not 256 
as yet established. However, given, the widespread use of opioids, it is anticipated that a large number 257 
of patients are possibly at risk of cortisol deficiency.  258 
The altered HPA axis function of opioid users improves or returns to normal after discontinuation 259 
or reduction in the dose of the drug
36, 37, 50, 51, 53, 54
 but the time interval of this has not been 260 
systematically studied. Interestingly, Nenke et al., in a pilot, randomized, double-blind, placebo-261 
controlled crossover study with 17 patients on long-term opioid therapy for chronic non-cancer pain 262 
and mild hypocortisolism (defined by a plasma cortisol response ≤350 nmol/L at 60 min following a 263 
cold pressor test), found that hydrocortisone therapy (10 mg/m
2
/day) led to improvement in vitality 264 
and pain tolerance compared to placebo
77
.  265 
In summary, opioids exert inhibitory actions on the HPA axis by acting at various levels. Although 266 
it could be argued that hypocortisolism is an adaptive response to opioids, the reported cases of 267 
improvement of clinical manifestations resembling those of cortisol deficiency after glucocorticoid 268 
administration
52, 53, 74, 77 
and the description of Addisonian crises whilst on these agents
16, 54
 suggest 269 
that, at least in some patients, hypocortisolism is of clinical significance. Further studies are needed to 270 
define the prevalence of hypoadrenalism with different opioids at various regimes and routes, to 271 
establish the clinical significance and potential consequences/adverse outcomes of the biochemical 272 
findings (particularly if these reflect modest changes in the HPA axis) and to provide clear guidance 273 
on the reversibility and the time course of the hormonal changes following withdrawal or reduction of 274 
opioid dose. Although the existing literature cannot provide robust evidence for safe and cost-275 
effective clinical guidelines, patients on opioids should be considered at risk of hypoadrenalism and 276 
checking an early morning plasma cortisol (particularly in the presence of relevant clinical 277 
manifestations) is a sensible approach. Further dynamic assessment of the HPA axis will depend on 278 
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the results of the basal cortisol. The frequency of the HPA axis assessment is not known but certainly 279 
the presence of symptoms/sings of cortisol deficiency should prompt investigations towards this 280 
direction. 281 
 282 
Somatotroph axis 283 
 284 
In animal models, acute opioid administration stimulates growth hormone (GH) secretion
78, 79
. On 285 
the other hand, chronic administration has led to no
61, 80
 or to stimulatory effect
81
. Studies on the 286 
pathways and mechanisms involved on the effects of opioids on GH release show that various types 287 
of opioid receptors (μ, κ, δ) are implicated, but their activation effects vary between reports82-84. Α 288 
reset of the hypothalamic GH pulse generator via opioid receptor stimulation is also a possible 289 
mechanism
85
. Treatment of rats with antiserum against GHRH inhibited the GH stimulatory response 290 
to different types of opiates
86, 87
. In addition, opioids exert inhibitory effect on somatostatin release
88
 291 
and action
89
. Finally, chronic treatment with morphine decreased GH mRNA levels in rat pituitary and 292 
concomitant administration of naloxone inhibited this
90
. Notably, gender may influence the effects of 293 
these drugs on the GH secretory dynamics. Continuous morphine exposure of male rats resulted in 294 
increased basal and mean GH concentrations, as well as in a modest increase of the GH pulse 295 
frequency but not of pulse amplitude; in females, morphine, apart from a marked reduction in the 296 
pulse amplitude, had little effect on other parameters of GH secretion
91
. 297 
In human subjects, there are acute stimulatory effects of opioids on GH secretion which relate with 298 
the dose offered
92, 93
. Thus, intravenous morphine at doses of 5 mg and 10 mg did not promote GH 299 
secretion but a higher dose of 15 mg did
92, 94, 95
. Notably, administration of a Met-enkephalin analogue 300 
G-DAMME, in healthy men combined with a maximally stimulatory dose of a GHRH analogue 301 
resulted to an enhancing effect of the GHRH-induced GH release, suggesting that other mechanisms 302 
are also implicated
93
. Data on possible sex differences are contradictory. Naloxone infusion decreased 303 
the growth hormone-releasing hormone (GHRH)-induced GH release in healthy women but had no 304 
effect in normal men
96
. On the other hand, in another study, naloxone significantly blunted 305 
the GH response to GHRH in healthy male volunteers
97
. 306 
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Humans treated with intrathecal opioids (morphine and hydromorphine) for non-malignant pain 307 
had significantly lower serum insulin-like growth factor 1 (IGF-1) levels compared with controls; 308 
17% of the subjects had IGF-1 concentrations more than two standard deviations below the mean, 309 
whilst 15% of them showed peak GH <3 μg/L during ITT16. Abnormal GH response on ITT was also 310 
detected in 26% of methadone-treated patients and in 31% of heroin addicts
98
. In this study, a 311 
maximal level of GH >9 μg/L or an increment over the baseline >10 μg/L were defined as criteria of a 312 
normal response; using the cut-off of <3 μg/L, a compromised GH response would be found in 5% 313 
and 6% of methadone and heroin users, respectively. Finally, chronic pain patients on oral opioids had 314 
no abnormal IGF-1 levels or a difference in GH response to the glucagon stimulation test when 315 
compared to a control group receiving non-opioid analgesia
99
; a suboptimal GH response found in two 316 
cases was finally attributed to obesity. 317 
The above data demonstrate the complexity of the effects and relevant mechanisms of opioids on 318 
the GH axis. Overall, acute administration of opioids increases GH secretion but the impact of chronic 319 
use varies considerably. Gender, opioid type, route and dose are factors that influence the action of 320 
opioids on GH release. The clinical significance of these findings in patients using long-term opioids 321 
remains to be elucidated. 322 
 323 
Prolactin  324 
 325 
Opioids can have a stimulatory effect on PRL secretion mediated by μ-, κ- and δ-opioid receptors 326 
in the hypothalamus
100
.  327 
Acute administration (oral or intravenous) of morphine increases PRL in healthy men
101
 and 328 
postmenopausal women
94
. In women, sex steroids may alter the opioid-induced effects on PRL 329 
secretion; thus, whilst naloxone had no effect on PRL secretion in postmenopausal and 330 
hypogonadal women, as well as women in the early follicular phase of the menstrual cycle, 331 
when administered for 7 days in the luteal phase, it induced PRL release9.  332 
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In chronic use of opioids, the effects are variable. PRL levels have been found high in opioid 333 
addicted subjects and in opium smokers
18, 102, 103
. Furthermore, oral opioids for chronic pain increase 334 
PRL
104, 105
. On the other hand, morphine offered intrathecally for chronic non-cancer pain had no 335 
effect on PRL
16
. Finally, buprenorphine or methadone maintenance therapy for opioid dependence did 336 
not lead to high PRL
34, 106
.    337 
Opioid-induced hyperprolactinaemia can lead to painful gynecomastia, galactorrhoea and 338 
hypogonadism
104
.  339 
Bromocriptine has been successfully used in cases of hyperprolactinaemia due to opioid use
107
.  340 
Overall, high PRL can be detected in patients on opioids, although the effect of pain on this 341 
finding needs to be taken into account. The frequency of hyperprolactinaemia and the impact of dose, 342 
route and type of drug have not been clearly established, but the clinician needs to be aware of this 343 
potential consequence and its clinical sequelae (particularly on the gonadotroph axis). 344 
 345 
Hypothalamo-pituitary-thyroid axis 346 
 347 
Based on most animal studies, opioids have inhibitory effect on thyroid-stimulating hormone 348 
(TSH) secretion and this is observed mainly with pharmacological doses
108, 109
.  349 
In humans, acute intravenous administration of morphine in normal volunteers led to a significant 350 
increase in serum TSH and enhanced the response of TSH to thyrotropin-releasing hormone 351 
stimulation
110
.  352 
In chronic use of opioids for cancer pain and in opioid addicts, there was no difference in basal 353 
levels of TSH and peripheral thyroid hormones compared with from controls
16, 104, 111, 112
. However, 354 
opium smokers had lower TSH levels compared with healthy volunteers
102
.   355 
The potential clinical significance and the implications of these data remain to be elucidated and, 356 
therefore, at this stage, clinical recommendations cannot be provided. 357 
 358 
Arginine Vasopressin 359 
 360 
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    Opioids affect arginine vasopressin (AVP) secretion through μ-113 and possibly κ-opioid 361 
receptors
114
. 362 
Acute opioid administration can lead to a rise in AVP levels. Fentanyl offered in two continuous 363 
intravenous infusions in five healthy volunteers increased plasma AVP in a dose-dependent 364 
manner
115
. Notably, a case of a patient on fentanyl patches who developed syndrome of inappropriate 365 
antidiuretic hormone secretion has been published 
116
. 366 
Boulton et al. showed that in patients undergoing coronary artery bypass surgery, the levels of 367 
AVP were significantly higher with fentanyl than with sufentanil during induction of anaesthesia
117
. 368 
Administration of extradural injection of morphine six hours after surgery in six patients produced 369 
increase in plasma AVP
118
. Bozkurt et al., in a series of children undergoing surgery (major genito-370 
urinary or abdominal operations), found that both a single dose of epidural morphine post-induction or 371 
morphine infusion led to increase in serum ADH levels
119
.  372 
Overall, the studies on the impact of exogenous opioids on AVP in humans are confounded by the 373 
differences in the fluid status of the subjects, as well as by the side effects of opioids, including 374 
hypotension and nausea, which can stimulate AVP release. Therefore, the interpretation of the 375 
published data and the extraction of robust conclusions for clinical practice remain challenging. 376 
 377 
Bone Mineral Density and Fracture Risk 378 
 379 
Exogenous opioids have a negative impact on bone health. Opioid-induced hypogonadism, as well 380 
as direct action of these drugs on bone formation are potential contributing factors. Osteoblasts 381 
express opioid receptors and opioids inhibit the growth of human osteoblast tissue cultures; this effect 382 
was prevented by opioid antagonists
120
. Furthermore, opioids inhibit osteocalcin production in 383 
osteoblast tissue cultures
120
.  384 
Male chronic heroin users have significantly lower vertebral bone mineral density (BMD) 385 
compared with healthy age- and sex-matched control subjects
121
. In a cross-sectional study of patients 386 
taking methadone maintenance therapy, BMD was lower from control values throughout the skeleton 387 
in men but not in women; notably in this series, the male patients had lower serum testosterone than 388 
15 
 
the controls
122
. In another study, 50% of men and 21% of women on chronic oral opioids had 389 
osteopenia; in this report, however, males had used opioids for a longer period and had higher 390 
prevalence of hypogonadism compared with women
15
. In addition, in a study of 14 males on 391 
intrathecal opioids for chronic non-malignant pain and hypogonadism, osteoporosis was observed in 392 
21% and osteopenia in 50%
25
. In a cross-sectional analysis of adults aged 17 years and older from the 393 
Third National Health and Nutrition Examination Survey, opioids were associated with significantly 394 
reduced BMD besides anticonvulsants
123
.  395 
In a case control study from a nation-wide register in Denmark, there was increased fracture risk in 396 
users of morphine and other opioids
124
. Notably, the authors suggested that this increase, which was 397 
observed even on very low doses, may be related with the risk of falls owing to the acute central 398 
nervous system effects of opioids
124
. This view was further supported by a nested case-control study 399 
using the UK-based General Practice Research Database in which a clear dose-response relationship 400 
between current cumulative opioid use and risk of fracture was found
125
; thus, current light use of 401 
opioids was associated with increased the risk of fractures in adults with non-cancer pain, particularly 402 
during the initial weeks of administration, whilst current heavy cumulative opioid use was not, 403 
particularly in women
125
. Finally, the contribution of limitations in mobility (due to chronic pain) on 404 
the higher risk of fractures cannot be excluded.  405 
There is no consensus on the monitoring of the BMD in patients on opioids but those with risk 406 
factors and particularly hypogonadism require assessment. Discontinuing the opioid, if possible, and 407 
treatment of osteoporosis or osteopenia according to the current guidelines are management 408 
approaches.  409 
 410 
Conclusions and future perspectives 411 
 412 
Exogenous opioids have effects on multiple levels of the endocrine system through mechanisms 413 
which are still not fully elucidated (Table 2). Hypogonadism is the most well recognised consequence 414 
of opioid use which, however, may remain undiagnosed with potential adverse sequelae for the 415 
patients. Although less frequent, cortisol deficiency can be found. The data on the impact of opioids 416 
16 
 
on GH and TSH are less clear and often complex, whereas hyperprolactinaemia can be occasionally 417 
detected. AVP levels may be increased in patients on these drugs but a number of confounding factors 418 
do not allow clear conclusions to be drawn. Of particular importance is the negative impact of opioids 419 
on bone health, which may be overlooked during the care of these patients.  420 
Discontinuation or reduction of the opioid and, in cases of chronic pain, consideration of 421 
alternative therapies for pain relief are potential management options. Hormonal replacement, 422 
especially when the above measures are not practically feasible, needs to be considered (Table 2). 423 
Awareness of the endocrine effects of opioids by all specialists prescribing or managing patients on 424 
these drugs is vital, particularly given the expanding dimensions of this problem as a global epidemic.  425 
Further research is needed to clearly establish the prevalence of hormonal abnormalities with 426 
various regimes, doses and routes of opioids, the impact of partial agonists (like buprenorphine) and 427 
the clinical significance of the biochemical findings from the HPA axis. Finally, well designed 428 
prospective rather than cross-sectional studies taking into account the effect of confounding factors 429 
(like other co-morbidities, drugs or pain) are needed to clarify the long-term benefits and risks of 430 
hormonal treatment and its effects on other areas, including pain sensitivity and potential reduction in 431 
opioid dose, and recovery of patients on methadone for opioid use disorder. These will finally lead to 432 
safe and cost-effective clinical guidelines, but until these become available, periodical assessment of 433 
the gonadal and adrenal function (particularly when relevant clinical manifestations are present) and 434 
evaluation of bone health status are advised.   435 
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